Treatment of human diseases involving dysregulation or dysfuncti

Details Treatment of human diseases involving dysregulation or dysfuncti Treatment of human diseases involving dysregulation or dysfuncti

1991-06-07

1993-02-23

Waddell, Frederick E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514903, 514906, A61K 3170

Patent

active

051890267

ABSTRACT:
A method of preventing, treating and/or controlling diseases caused by dysregulation and/or dysfunction of various portions of the nervous system which comprises administering to a patient, an effective amount of a compound of the avermectin family, e.g. ivermectin, in single or multiple doses of up to 1.6 mg/kg at intervals of from 3 days to 4 months.

REFERENCES:
patent: 4171314 (1979-10-01), Chabala et al.
patent: 4173571 (1979-11-01), Chabala et al.
patent: 4199569 (1980-04-01), Chabala et al.
patent: 4201861 (1980-05-01), Mrozik et al.
patent: 4206205 (1980-06-01), Mrozik et al.
patent: 4310519 (1982-01-01), Albers-Schonberg et al.
patent: 4333925 (1982-06-01), Buhs et al.
patent: 4831017 (1989-05-01), Egerton
patent: 4853372 (1989-08-01), Williams et al.
patent: 4963667 (1990-10-01), Chiu et al.
patent: 5070015 (1991-12-01), Pentuch et al.
Avery's Drug Treatment, 3rd edition, AIDS Press (1987) pp. 1114-1116.
Bennett, Javma, 189, 100-104, (1986).
Chalmers, et al., Em. J. Pharmacol., 129, 371-374, (1986).
Martin, et al., Br. J. Pharmacol., 98, 747-756, (1989).
Mart, Resland News, 151, 1317, (1991).
Gisslinger, et al., Lancet, 336, 1078 (1990).
Levine, et al., Science, 226, 547-49 (1984).
Thompson, et al., Ann. Rheum. Dis. 21, 370-77 (1962).
Bland, et al., Arthritis and Rheum., 11, 72-79, (1968).
Kugelber, Electroceneph. Clin. Neurophysiol. Suppl 22 103-111 (1962).
Pacque, et al., Lancet, 335, 1377-1380 (1990).
Pacque, et al., Lancet, 336, 1486-89 (1990).
Campbell, et al., Science, 221, 823-828, (1983).
Campbell, et al., J. Vet. Pharmacol. Therap., 7 1-16, (1984).
Terada, et al., Exp. Parasitol., 57 149-157 (1984).
Hagbarth, J. Neurol. Neurosurg. Psychia., 23 222-227 (1960).
Hagbarth, et al., J. Neurol. Neurosurg. Psychia., 31 207-213 (1968).
Hassan et al., J. Neurol Neurosurg. Pschia., 43 1132-1136 (1980).
Knutsson, Triangle, 21, 13-20 (1982).
Knutsson, et al., Scand. J. Rehabil. Med., 12, 93-106 (1980).
Knutsson, et al., J. Neurol. Sci., 53, 187-204 (1982).
McNamara, et al., Neuropharmacol., 27, 563-68 (1988).
McNamara, Epilepsia, 30, 513-518 (1989) (Suppl. 1).
Coward, Triangle, 20, 151-158 (1981).
Davies, Br. J. Pharmacol., 76, 473-481 (1982).
Davies, et al., Br. J. Pharmacol., 78, 137-142 (1983).
Sayers, et al., Arzneimitted-Forschung, 30, 793-803 (1980).
Kerr, et al., Brain Res., 405, 150-154 (1987).
Price, et al., Nature, 307 71-74 (1984).
Bowery et al., Neuropharmacol., 23, 219-234 (1984).
Olsen, et al., Fase, B. J., 4, 1469-1480 (1990).
Erickson, Sci. Amer., 264 (5) 124 (1991).
Porter, et al., Cleveland Clin. Quart., 51, 293-305 (Summer 1984).
Sigel, et al., Mol. Pharmacol., 32, 749-52 (1987).
Soderlund, et al., Biochem. Biophys. Res. Comm. 146, 692-698 (1987).
Kirkness, et al., Eur. J. Pharmacol., 150, 385-388 (1983).
Robertson, Br. J. Pharmacol., 98, 167-176 (1989).
Chu, et al., Neurol., 37, 1454-59 (1987).
Bhisitkul, et al., Exp. Brain Res., 66, 659-663 (1987).
Crichlow et al., Neuropharmacology, 25 (10, 1085-1088 (1986).
Diggs et al., Laboratory Animal Science, 40 (1), 68-71 (1990).

Affiliated with

Also associated with

Rating

Treatment of human diseases involving dysregulation or dysfuncti does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of human diseases involving dysregulation or dysfuncti, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of human diseases involving dysregulation or dysfuncti will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2204961